Merck & Co. (MRK) : Godshalk Welsh Capital Management reduced its stake in Merck & Co. by 1.37% during the most recent quarter end. The investment management company now holds a total of 32,421 shares of Merck & Co. which is valued at $1.7 Million after selling 450 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 13, 2016.Merck & Co. makes up approximately 1.84% of Godshalk Welsh Capital Management’s portfolio.
Other Hedge Funds, Including , Hanlon Investment Management sold out all of its stake in MRK during the most recent quarter. The investment firm sold 75,162 shares of MRK which is valued $4 Million.Salient Trust Co Lta reduced its stake in MRK by selling 19,960 shares or 25.01% in the most recent quarter. The Hedge Fund company now holds 59,838 shares of MRK which is valued at $3.2 Million. Merck & Co. makes up approx 0.39% of Salient Trust Co Lta’s portfolio.Jennison Associates reduced its stake in MRK by selling 724,201 shares or 22.81% in the most recent quarter. The Hedge Fund company now holds 2,450,821 shares of MRK which is valued at $131.4 Million. Merck & Co. makes up approx 0.14% of Jennison Associates’s portfolio.Jackson Wealth Management reduced its stake in MRK by selling 1,614 shares or 3.37% in the most recent quarter. The Hedge Fund company now holds 46,289 shares of MRK which is valued at $2.5 Million. Merck & Co. makes up approx 0.96% of Jackson Wealth Management’s portfolio.
Merck & Co. opened for trading at $55.81 and hit $56.67 on the upside on Wednesday, eventually ending the session at $56.57, with a gain of 1.74% or 0.97 points. The heightened volatility saw the trading volume jump to 96,01,393 shares. Company has a market cap of $156,587 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.